Skip to main content
Albert Jang, MD, Oncology, Cleveland, OH

AlbertJangMD

Oncology Cleveland, OH

Medical Oncology Fellow

Dr. Jang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Jang's full profile

Already have an account?

  • Office

    11100 Euclid Avenue
    Cleveland, OH 44106

Education & Training

  • Case Western Reserve University/University Hospitals Cleveland Medical Center
    Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2023 - 2025
  • Tulane University
    Tulane UniversityChief Residency, Internal Medicine, 2022 - 2023
  • Tulane University
    Tulane UniversityResidency, Internal Medicine, 2019 - 2022
  • Baylor College of Medicine
    Baylor College of MedicineClass of 2019, MD
  • Rice University
    Rice UniversityBS, Biochemistry and Cell Biology, 2011 - 2014

Certifications & Licensure

  • LA State Medical License
    LA State Medical License 2022 - 2024
  • American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Inferior Survival Among Polycythemia Vera Patients Exhibiting Body Mass Index Reduction.  
    Albert Jang, Hussein Hamad, Sravanti Teegarapavu, Sarvari V. Yellapragada, Gustavo A. Rivero, SN Comprehensive Clinical Medicine, 4/10/2023
  • PD-L1 Expression and Treatment Implications in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review  
    Albert Jang, Patrick L. Sweeney, Pedro C. Barata, Vadim S. Koshkin, Kidney Cancer, 3/23/2021
  • Systemic Lupus Erythematosus with Autoimmune Myelofibrosis, Immune Thrombocytopenic Purpura, and Widespread Lytic Bone Lesions Successfully Treated with Rituximab and ...  
    Tejasvi K. Dasari, Jake Jacob, Annie Dai, Albert Jang, Lee Bach Lu, SN Comprehensive Clinical Medicine, 1/22/2021
  • Join now to see all

Abstracts/Posters

  • Successful Management of Locally Advanced and Oligometastatic Urothelial Carcinoma with Pembrolizumab-based Induction Regimen Followed by Consolidative Radical Resecti...
    Albert Jang, Tanya Jindal, Adam C. Calaway, Jonathan E. Shoag, Vadim S. Koshkin, Pedro C. Barata, NCCN Conference, Orlando, FL, 4/6/2024
  • Clinicogenomic characterization of patients with rapid tumor progression versus sustained response to frontline systemic therapy for metastatic urothelial carcinoma (mUC)
    Albert Jang, Sulin Wu, Hamsa Latha Sampath Kumar, Ravi Kumar Kyasaram, Chen-Han Wilfred Wu, Laura Bukavina, Adam C Calaway, Jorge A Garcia, Pedro C Barata, Prateek Men..., ASCO GU 24, San Francisco, CA, 1/25/2024
  • Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA.
    Reagan Barnett, Sree M Lanka, Keelia M Clemens, Lesli Ann Kiedrowski, Hani M Babiker, Alan Haruo Bryce, Haley M Meyer, Yujin Choi, Rohan Garje, Xin Gao, Richard Y Chan..., ASCO, Chicago, IL, 6/1/2023
  • Join now to see all

Authored Content

  • All in for the PatientJune 2020
  • Promote a culture of medical school peer educationJune 2019

Press Mentions

  • ASCO GU 2023: Comparison of ctDNA Between African American and Caucasian Patients with CRPC Post Abiraterone And/or Enzalutamide
    ASCO GU 2023: Comparison of ctDNA Between African American and Caucasian Patients with CRPC Post Abiraterone And/or EnzalutamideFebruary 16th, 2023
  • AUA 2022: Prospective Evaluation of ctDNA in Detecting Early Progression on Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Cancers
    AUA 2022: Prospective Evaluation of ctDNA in Detecting Early Progression on Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary CancersJune 13th, 2022
  • Alemtuzumab as Part of Conditioning Therapy for Graft-Vs-Host Disease in Children and Young Adults
    Alemtuzumab as Part of Conditioning Therapy for Graft-Vs-Host Disease in Children and Young AdultsJuly 24th, 2022
  • Join now to see all

Other Languages

  • Chinese (Mandarin), Spanish